Lunit Showcases Breakthroughs in AI for Cancer Care at ASCO 2025
Lunit, a global leader in AI-driven cancer diagnostics and therapeutics, is set to make waves at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. With presentations covering 12 crucial studies, these insights mark a significant step forward in the application of artificial intelligence in precision oncology.
Among the most notable studies is a collaboration with Japan's National Cancer Center Hospital East, which examined HER2 expression in biliary tract cancer (BTC) patients. By utilizing Lunit's advanced AI-powered analyzer, researchers found that the AI scores were closely aligned with those assigned by pathologists on a cohort of 288 patients. Among those receiving trastuzumab deruxtecan (T-DXd), a remarkable 50% objective response rate (ORR) was observed in patients with a higher prevalence of HER2-intense tumor cells. This offers substantial implications for treatment accessibility, indicating that AI analysis can potentially identify additional candidates for targeted therapies.
Another groundbreaking study evaluated the reliability of the AI model in assessing PD-L1 expression in lung cancer patients, probing one of Japan's largest nationwide observational cohorts, LC-SCRUM. This prospective study, which included a total of 949 patients, yielded a commendable 70% concordance rate when comparing AI assessments to those made by three expert pathologists. Specific subgroups exhibited even more impressive agreements, underscoring the AI's potential to reveal treatment candidates who might otherwise be excluded due to low PD-L1 scores.
Moreover, Lunit's research extended into gastric cancer, where an innovative AI model was developed to predict CLDN18.2 expression. Traditionally obtained through immunohistochemistry (IHC), this model sought to obviate some of the limitations associated with tissue quantity and cost. The AI demonstrated an impressive AUROC value exceeding 0.751, indicating its efficacy in pre-screening patients likely to respond positively to therapies targeting CLDN18.2. Enhanced predictions based on immune phenotypes also promised to play a critical role in tailoring first-line treatment options.
Brandon Suh, CEO of Lunit, remarked on the progress of their ASCO presentations, stating, "The culmination of our extensive research has led to AI becoming a clinically reliable tool that not only improves image reading but also enhances treatment selection strategies. From HER2 assessments in biliary tract cancer to PD-L1 evaluations in lung cancer, our models aim to unveil treatment opportunities that might otherwise be missed." His comments highlight the transformative power of AI in the realm of cancer therapy.
Lunit is set to present several additional abstracts, covering a diverse array of topics within cancer research. These include investigations into subcellular profiling of membrane proteins and the use of deep learning to analyze endothelial cell behavior in relation to immunotherapy outcomes.
During the ASCO event, visitors can find Lunit at Booth #26149, where they will showcase their AI solutions and findings with the potential to reshape cancer diagnostics and treatment methodologies.
Lunit’s Key Presentations at ASCO 2025
Some of the significant presentations by Lunit planned for the ASCO meeting include:
- Artificial intelligence-based prediction of claudin 18.2 expression to guide treatment decisions in gastric cancer patients.
- Insights into protein drug-targetability through AI-powered subcellular expression profiling.
- AI-driven quantitative scoring of membrane-specific HER2 expression to predict trastuzumab efficacy in biliary tract cancer participants.
- A predictive AI model for assessing response to immune checkpoint inhibitors from pre-treatment CT scans.
- AI analysis of tumor microenvironments relating to cancer treatment responses, particularly focusing on lymphocyte infiltration.
Reflecting on the significance of their AI solutions in cancer care, Lunit aims to continue its pioneering mission. Founded in 2013, this innovative company has dedicated itself to overcoming cancer challenges through advanced technology. Their FDA-cleared Lunit INSIGHT suite is now leveraged in over 4,800 medical institutions worldwide, expediting drug development and potentially saving countless lives.
Frequently Asked Questions
What main studies is Lunit presenting at ASCO 2025?
Lunit is presenting 12 studies at ASCO 2025, focusing on AI applications in oncology, including HER2 analysis in biliary tract cancer and PD-L1 evaluations in lung cancer.
How can AI improve cancer diagnostics according to Lunit?
Lunit's AI tools provide robust analyses that enhance precision in treatment selection, allowing for the identification of previously overlooked treatment candidates.
Where can attendees find Lunit during the conference?
Attendees can visit Lunit at Booth #26149 to explore their latest AI-powered cancer diagnostic solutions and research findings.
What is the mission of Lunit?
Lunit's mission is to conquer cancer through AI, developing cutting-edge diagnostic solutions that enable effective diagnosis and tailored treatment strategies.
In what ways is Lunit influencing the future of cancer care?
By integrating AI into cancer diagnostics, Lunit strives to expand access to treatment and refine patient outcomes through data-driven decision-making.
